List of Excipients in Branded Drug LYRICA

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Parke-Davis Div of Pfizer Inc	LYRICA	pregabalin	0071-1012	FERROSOFERRIC OXIDE
Parke-Davis Div of Pfizer Inc	LYRICA	pregabalin	0071-1012	GELATIN
Parke-Davis Div of Pfizer Inc	LYRICA	pregabalin	0071-1012	LACTOSE MONOHYDRATE
Parke-Davis Div of Pfizer Inc	LYRICA	pregabalin	0071-1012	POTASSIUM HYDROXIDE

Lyrica Excipient Strategy and Commercial Opportunities for Pregabalin

Last updated: August 4, 2026

Lyrica, Pfizer’s brand of pregabalin, has a mature small-molecule market with extensive generic competition. The main commercial opportunity is no longer basic pregabalin substitution. It is differentiated delivery: lactose-free capsules, palatable oral liquids, sprinkle products, orally disintegrating tablets, modified-release systems, and formulations designed for renal dosing or adherence. Pregabalin’s high aqueous solubility and dose-dependent pharmacokinetics make simple immediate-release products relatively accessible, while taste, capsule size, excipient tolerability, and controlled release create practical product-development barriers.

What is Lyrica and which dosage forms are FDA-approved?

Lyrica contains pregabalin, a gamma-aminobutyric acid analog used for diabetic peripheral neuropathy, postherpetic neuralgia, fibromyalgia, and adjunctive treatment of partial-onset seizures. FDA-approved dosage forms have included immediate-release capsules, oral solution, and Lyrica CR extended-release tablets (FDA, 2023a; FDA, 2023b).

Product	Strengths or dose range	Release profile	Primary excipient opportunity
Lyrica capsules	25, 50, 75, 100, 150, 200, 225 and 300 mg	Immediate release	Capsule shell, lactose replacement, color, fill uniformity
Lyrica oral solution	20 mg/mL	Immediate release	Taste masking, preservative system, sugar-free positioning
Lyrica CR tablets	82.5, 165 and 330 mg	Extended release	Matrix technology, dose-dumping control, tablet size and robustness
Generic pregabalin	Multiple strengths and manufacturers	Mainly immediate release	Cost, manufacturing efficiency, differentiated excipients

Pregabalin is not a biologic. Products referencing Lyrica are approved through the abbreviated new drug application pathway and are generics, not biosimilars. FDA approval depends on pharmaceutical equivalence and bioequivalence, subject to the reference product’s dosage form and labeling requirements (FDA, 2023c).

What excipients are used in Lyrica capsules and oral solution?

Lyrica’s immediate-release products use conventional excipient systems. The capsule formulation contains lactose monohydrate, corn starch and talc in the fill, with gelatin and colorants in the shell. Exact colorant composition varies by strength. The oral solution uses a buffered aqueous vehicle, preservatives, sweetener and flavoring components (FDA, 2023a).

Lyrica capsule excipients

The capsule platform is technically straightforward:

• Lactose monohydrate acts as a diluent.
• Corn starch supports powder processing and capsule-fill performance.
• Talc improves flow and reduces adhesion.
• Gelatin provides the capsule shell.
• Titanium dioxide and strength-specific colorants provide opacity and product identification.

The commercial weakness is the use of lactose and gelatin. These excipients are inexpensive and well established, but they restrict positioning for patients seeking lactose-free, vegetarian, halal or kosher dosage forms. They also create opportunities for generic manufacturers to differentiate without changing the active ingredient or release profile.

Lyrica oral-solution excipients

The oral solution contains a buffered phosphate system, methylparaben, propylparaben, sucralose, artificial strawberry flavor and purified water, according to the FDA prescribing information (FDA, 2023a).

The formulation creates four development targets:

1. Palatability over the full labeled dose range.
2. Preservative compatibility and microbial control.
3. Chemical stability in multi-dose packaging.
4. Accurate dosing through an oral syringe or other dosing device.

A 20 mg/mL solution delivers 300 mg in 15 mL. That volume is clinically manageable but commercially relevant. A higher-concentration solution could reduce administration volume, but it would require new stability, palatability, viscosity, dose-delivery and regulatory work.

What excipient strategies can differentiate generic pregabalin?

The most attractive excipient strategies are those that solve a patient or manufacturing problem without creating a difficult bioequivalence pathway.

Lactose-free and gelatin-free capsules

A lactose-free capsule can replace lactose with microcrystalline cellulose, mannitol, dibasic calcium phosphate or another established filler. The formulation must preserve:

• Blend uniformity at low-dose strengths.
• Capsule-fill weight control.
• Dissolution across the full strength range.
• Powder flow during high-speed encapsulation.
• Stability under commercial packaging conditions.

A vegetarian capsule shell based on hypromellose can replace gelatin. This change has limited pharmacokinetic significance but has commercial value in retail, institutional and international markets. The opportunity is strongest where the product can be labeled lactose-free or vegetarian without a significant price premium.

Low-cost, high-throughput capsule systems

Pregabalin has multiple strengths, and manufacturers can reduce complexity through a common blend or proportional formulation. A common blend can lower validation and inventory costs, but the 25 mg and 50 mg strengths create a low-dose uniformity challenge. Content uniformity is more difficult when pregabalin represents a small fraction of total capsule fill.

Excipients with strong flow and low segregation behavior can improve:

• Weight variation.
• Content uniformity.
• Encapsulation speed.
• Yield.
• Batch-to-batch consistency.

The largest commercial benefit is often manufacturing margin rather than a premium selling price.

Sprinkle and easy-open formats

A sprinkle capsule or sachet could target patients with swallowing difficulty. The product must preserve dose uniformity after opening and mixing with soft food or liquid. Relevant development questions include:

• Whether the pellets or powder remain physically stable after opening.
• Whether food changes dissolution.
• Whether pregabalin adheres to containers or food vehicles.
• Whether the label can support administration through feeding tubes.
• Whether the product remains therapeutically equivalent to the reference capsule.

A sprinkle formulation may require a new dosage-form strategy rather than a simple generic capsule. That increases development cost but can create a differentiated product with fewer direct substitutes.

Taste-masked oral liquid

The oral solution is a clear target for excipient innovation. Pregabalin has a noticeable taste profile, and the current sweetener-flavor system may not be optimal for all patients.

Potential approaches include:

• Sucralose and acesulfame potassium combinations.
• Polyol-based systems such as sorbitol or xylitol.
• Flavor systems with strawberry, berry or citrus profiles.
• Ion-exchange resins.
• Cyclodextrins.
• Coated microparticles or taste-masked granules suspended in a vehicle.

A true taste-masked suspension may improve palatability but creates new requirements for redispersibility, dose uniformity, sedimentation, particle-size control and in-use stability. A liquid with a new excipient system may remain an ANDA product if it is pharmaceutically equivalent and bioequivalent, but a substantial change in dosage form or formulation can move the product toward a 505(b)(2) pathway.

Preservative-free or unit-dose liquid

The current multi-dose oral solution uses parabens. A preservative-free unit-dose product could target pediatric, institutional and home-care markets. The tradeoff is packaging cost and supply-chain complexity.

Commercial formats include:

• Unit-dose oral syringes.
• Single-use sachets.
• Blow-fill-seal containers.
• Small-volume bottles with child-resistant closures.

Unit-dose packaging may reduce dosing errors and improve compliance, but the product must support preservative-free microbiological control through packaging and validated manufacturing.

What formulation patents protect pregabalin products?

Pregabalin formulation protection has been narrower and less commercially durable than the original compound and method-of-use estate. Immediate-release generic capsules generally depend on formulation design, manufacturing controls and regulatory compliance rather than a broad, blocking excipient patent.

Protection category	Commercial relevance	Typical risk
Pregabalin compound patent	Historically central to Lyrica exclusivity	Expired
Neuropathic-pain method patents	Historically supported brand protection and litigation	Mostly expired or commercially weakened
Immediate-release capsule formulations	Limited blocking power where excipients are conventional	Low to moderate
Oral-solution formulations	Can protect preservative, flavor, concentration or stability systems	Moderate for narrow claims
Extended-release formulations	Stronger opportunity for matrix, coating and dosing technology	Moderate to high
Manufacturing processes	Can protect particle size, crystallinity, granulation or impurity control	Depends on claim scope and design-around options
Device and packaging patents	Relevant to unit-dose liquid and dosing systems	Usually narrow and product-specific

The key distinction is between a patent covering pregabalin itself and a patent covering a particular formulation. The compound patent blocked generic entry for the active ingredient. A formulation patent usually blocks only products that practice the claimed excipient composition, process or release technology.

Lyrica CR and extended-release protection

Lyrica CR was developed to provide once-daily extended release. Its commercial strategy relied on controlled-release technology rather than a new active ingredient. Extended-release products can create stronger technical barriers because they require control of:

• Drug release over the intended dosing interval.
• Food effects.
• Dose dumping.
• Tablet erosion or matrix integrity.
• In vitro-in vivo correlation.
• Inter-subject pharmacokinetic variability.

Extended-release pregabalin is a more defensible formulation opportunity than a conventional immediate-release capsule. The market is smaller, however, because patients and payers often favor low-cost immediate-release generics.

When did Lyrica lose exclusivity and generic entry?

Lyrica’s principal U.S. compound protection expired after pediatric exclusivity extended the relevant patent term into late 2018. FDA approved the first generic pregabalin capsules and oral solution in 2019, allowing broad generic competition (FDA, 2019; Pfizer, 2019).

Milestone	Date or period	Commercial effect
Lyrica U.S. approval	2004	Established the branded pregabalin market
U.S. compound patent protection	Extended into late 2018	Delayed broad generic entry
First U.S. generic approvals	2019	Opened immediate-release competition
Generic price competition	2019 onward	Reduced substitution economics for undifferentiated products
Differentiated-formulation opportunity	Current market	Shifts value toward delivery, tolerability and manufacturing

The U.S. Food and Drug Administration approved multiple generic manufacturers for pregabalin capsules and oral solution. Generic entry reduced the value of conventional capsule claims and increased the importance of cost structure, supply reliability and channel access.

Which companies challenged Lyrica patents?

Lyrica faced generic challenges before the end of U.S. patent protection. Generic companies, including Teva Pharmaceuticals, filed Paragraph IV certifications against listed Pfizer patents, leading to patent litigation and settlement activity. Pfizer disclosed Lyrica patent litigation and settlement arrangements in its public filings (Pfizer, 2018).

Paragraph IV challenges create commercial value even before a final invalidity ruling. A generic applicant may obtain:

• A possible first-filer position.
• A 180-day exclusivity opportunity.
• Settlement rights.
• A launch date before patent expiration.
• Leverage in licensing or supply negotiations.

For pregabalin, the market outcome was broad generic entry after the core protection period. The remaining legal value resides mainly in narrow formulation, method-of-use, manufacturing and device claims.

What is the Orange Book status of Lyrica?

The FDA Orange Book historically listed Lyrica patents covering pregabalin and certain methods of use. Orange Book listings are relevant because they determine the patent certifications required in an ANDA and provide the reference point for Paragraph IV litigation (FDA, 2024).

The practical Orange Book analysis for Lyrica has four parts:

1. Identify the reference listed drug and dosage form.
2. Separate expired compound patents from any active listed patents.
3. Review the patent use codes and corresponding labeling carve-outs.
4. Determine whether the proposed generic formulation falls within any listed formulation claim.

A listed method-of-use patent does not necessarily block a generic for all indications. A generic applicant can use a section viii statement to omit a patented indication when FDA labeling and the proposed use support that approach. The commercial risk depends on whether the patented use represents a large share of pregabalin demand.

How strong is the Lyrica patent estate for new excipient products?

The legacy Lyrica estate is weak for basic immediate-release products and stronger for technically differentiated delivery systems.

Product concept	Patent strength	Regulatory complexity	Commercial potential
Standard lactose-containing capsule	Low	Low	Low
Lactose-free capsule	Low to moderate	Low to moderate	Moderate
Gelatin-free capsule	Low to moderate	Low to moderate	Moderate
Palatable oral solution	Moderate	Moderate	Moderate
High-concentration oral solution	Moderate	Moderate to high	Moderate
Sprinkle capsule	Moderate	Moderate to high	Moderate to high
Orally disintegrating tablet	Moderate	Moderate	Moderate
Extended-release tablet	Moderate to high	High	Moderate
Unit-dose preservative-free liquid	Moderate	Moderate	Niche but defensible
Novel manufacturing process	Moderate to high	Moderate	Depends on scalability

A strong new patent position should claim a specific technical relationship, not merely the presence of a conventional excipient. Examples include a defined polymer ratio that controls release, a stable high-concentration liquid, a particle-size distribution that improves uniformity, or a taste-masking system that achieves a measurable dissolution and sensory profile.

What regulatory barriers affect pregabalin excipient products?

The regulatory pathway depends on whether the product remains pharmaceutically equivalent to the reference product.

ANDA pathway

An ANDA is most suitable for a product that matches the reference dosage form and demonstrates bioequivalence. Changes in inactive ingredients may be acceptable if they do not affect safety, performance or bioequivalence. FDA inactive-ingredient precedent, maximum daily exposure and route-specific safety are important considerations (FDA, 2019b).

The main technical studies may include:

• Comparative dissolution.
• Assay and content uniformity.
• Impurity and degradation analysis.
• Stability testing.
• In-use stability for liquids.
• Microbial limits and preservative effectiveness.
• Food-effect assessment where required.
• Pharmacokinetic bioequivalence.

505(b)(2) pathway

A 505(b)(2) application may be more appropriate for a new concentration, delivery system, route, release profile or dosing device that cannot be supported through a standard ANDA. This pathway can support differentiated products but may trigger listed-patent certifications and require additional clinical or pharmacokinetic evidence.

What commercial opportunities exist for pregabalin excipients?

The most investable opportunities are products with a clear use case and modest clinical-development burden.

High-probability opportunities

A lactose-free, gelatin-free generic capsule has the lowest technical risk. It can support pharmacy, hospital and international tenders, although price competition is severe.

A taste-masked oral solution has stronger differentiation. Pediatric and swallowing-impaired patients can support demand, particularly when the product is packaged with an oral syringe and has a stable, acceptable flavor.

A sprinkle formulation may command greater value because it addresses administration difficulty. The key risks are bioequivalence, food interaction and label restrictions.

A high-concentration liquid can reduce dosing volume, but the commercial case depends on whether patients, caregivers and payers value that benefit enough to offset formulation and regulatory costs.

An extended-release product offers the strongest technical differentiation. It also has the highest development risk and competes with inexpensive immediate-release pregabalin.

Revenue exposure

Pfizer reported approximately $5 billion in global Lyrica revenue in 2018, before the full effect of U.S. generic competition (Pfizer, 2019). That revenue base explains the scale of the generic opportunity, but it should not be used as a forecast for a new excipient product. Post-exclusivity value shifted from brand pricing to volume, manufacturing efficiency and differentiated delivery.

A generic manufacturer is likely to prioritize:

• High-volume capsule strengths.
• Reliable API sourcing.
• Low-cost excipient systems.
• Robust dissolution and content uniformity.
• Retail substitution.
• Institutional supply contracts.

A specialty manufacturer can pursue:

• Pediatric and geriatric administration.
• Feeding-tube compatibility.
• Vegetarian or allergen-sensitive positioning.
• Unit-dose packaging.
• Extended-release adherence products.
• Regional markets with limited generic competition.

How does Lyrica compare with competing neuropathic-pain drugs?

Pregabalin competes with gabapentin, duloxetine, amitriptyline and other treatments. Excipients matter most when the active ingredient has limited differentiation and the market is price sensitive.

Drug	Primary formulation opportunity	Competitive issue
Pregabalin	Taste masking, sprinkle, lactose-free capsule, extended release	Broad generic competition
Gabapentin	Oral solution, tablets, capsules, extended-release systems	Very mature generic market
Duloxetine	Enteric coating and capsule stability	Delayed-release manufacturing complexity
Amitriptyline	Low-dose tablets and liquid formulations	Low cost and extensive generic availability

Pregabalin has an advantage for liquid and modified-release innovation because its dosage range is broad and its indications include patients with swallowing or adherence challenges. Its disadvantage is the large number of immediate-release generics.

What manufacturing and geographic barriers affect pregabalin products?

Pregabalin production is less dependent on complex biologic manufacturing than many branded drugs. The main barriers are commercial and operational:

• API quality and supply continuity.
• Control of polymorphic or particle-size attributes where relevant.
• Low-dose blend uniformity.
• Capsule-filling throughput.
• Liquid preservative and microbial control.
• Packaging compatibility.
• Supply qualification across multiple jurisdictions.
• Country-specific excipient restrictions and labeling.

Geographic opportunities are uneven. In the U.S., immediate-release pricing is compressed. In markets with fewer approved suppliers, a reliable lactose-free capsule or oral liquid can win through tender access. In Europe, prescription and reimbursement systems make generic pricing aggressive, while excipient preferences and national substitution rules create niche openings. In emerging markets, oral liquids and smaller pack sizes may be more valuable than advanced extended-release products.

Key Takeaways

• Lyrica is pregabalin, a small-molecule drug with extensive generic competition.
• The core compound and major historical method-of-use protections no longer provide a durable barrier to immediate-release generics.
• Conventional capsule excipients are inexpensive and easy to design around.
• The strongest commercial opportunities are taste-masked liquids, sprinkle products, lactose-free or gelatin-free capsules, unit-dose packaging and extended-release systems.
• Extended-release formulations have stronger patent potential but require more complex bioequivalence and performance work.
• Pregabalin products are generics, not biosimilars.
• Orange Book analysis remains important for listed patents, use codes and Paragraph IV strategy.
• Manufacturing efficiency and supply reliability are more valuable than broad composition claims for standard capsules.
• A differentiated excipient product needs a specific patient benefit, a credible regulatory pathway and claims that are difficult to design around.

FAQs About Lyrica Excipient Strategy and Pregabalin Formulation

Can a generic pregabalin capsule use different excipients from Lyrica?

Yes. A generic may use different inactive ingredients if the formulation meets FDA requirements for safety, pharmaceutical equivalence, bioequivalence, quality and labeling.

Is Lyrica oral solution suitable for pediatric formulation development?

It can support pediatric development because it is a liquid dosage form, but taste, dose volume, preservative exposure, packaging and dosing accuracy determine commercial attractiveness.

Does pregabalin have biosimilar competition?

No. Pregabalin is a chemically synthesized small molecule. Competing products are approved as generics through the ANDA pathway rather than as biosimilars.

Can a company patent a lactose-free pregabalin capsule?

A broad lactose-free claim is unlikely to provide strong protection by itself. A stronger patent would require a specific composition, manufacturing process or performance advantage that is novel and non-obvious.

Is extended-release pregabalin commercially attractive after generic Lyrica entry?

It can be attractive for adherence and reduced dosing frequency, but the product must overcome development costs, payer resistance and competition from low-cost immediate-release pregabalin.

References

1. U.S. Food and Drug Administration. (2019). FDA approves first generics of Lyrica. https://www.fda.gov
2. U.S. Food and Drug Administration. (2019b). Inactive ingredient database. https://www.accessdata.fda.gov
3. U.S. Food and Drug Administration. (2023a). Lyrica prescribing information. Pfizer Inc. https://labeling.pfizer.com
4. U.S. Food and Drug Administration. (2023b). Lyrica CR prescribing information. Pfizer Inc. https://labeling.pfizer.com
5. U.S. Food and Drug Administration. (2023c). Approved drug products with therapeutic equivalence evaluations. Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/
6. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. Orange Book database. https://www.accessdata.fda.gov/scripts/cder/ob/
7. Pfizer Inc. (2018). Annual report 2018. https://www.pfizer.com/investor/financial-reports
8. Pfizer Inc. (2019). Annual report 2019. https://www.pfizer.com/investor/financial-reports